Methotrexate levels in red blood cells of young people with Crohn's disease
Measures methotrexate levels over time in children and teenagers with Crohn's disease.
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Amsterdam, Enschede, Groningen, and Utrecht, NetherlandsSee the 4 sites
- Trial code
- Registry title
- Methotrexate in paediatric and adolescent Crohn’s disease: an observational study
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 215 people, planned
- Started
- 15 Jul 2026
- Expected to end
- 1 Feb 2030
- Type of study
- Interventional
- Record updated
- 30 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children, teenagers and young adults with Crohn's disease who are about to start methotrexate (MTX), alone or together with infliximab.
- Age
- 4-28 years
- Sex
- Women and men can join.
- Disease stage
- Crohn's disease proven by endoscopic, radiological and histologic findings.
- Earlier treatment
- Must be about to start MTX treatment, either alone or together with infliximab. Cannot be treated with a biologic agent other than infliximab.
Main reasons for not taking part
- Not able to receive MTX, as in usual care
- Treatment with a biologic agent other than infliximab
- Cannot read and understand the patient and family information sheets
- Informed consent of the patient not obtained when required
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age of 4-28 years
- Written informed consent of patient (if indicated) and parents (if indicated) has been obtained
- Proven diagnosis of Crohn’s disease based on endoscopic, radiological and histologic findings
- Will start MTX treatment monotherapy or combination therapy with infliximab
Who cannot take part
- Co-treatment with a biologic agent other than infliximab
- Not eligible to receive MTX, as in usual care
- Inability to read and understand the patient and family information sheets
- Informed consent of patient has not been obtained when required
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
- Medisch Spectrum TwenteEnschede, NetherlandsTaking people
- Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people
- Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
About the trial
What the trial wants to find out
[PK] Determination of MTX-PG concentrations and identification of accumulation patterns over time in RBCs. [PD] Association of MTX-PG concentration with MTX discontinuation due to a lack of efficacy or toxicity.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Methotrexate in paediatric and adolescent Crohn’s disease: an observational study
- Plain-language title
- Methotrexate levels in red blood cells of young people with Crohn's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 July 2026